Aurinia Pharmaceuticals (AUPH) financial statements
Aurinia Pharmaceuticals reported revenue of $283M in fiscal 2025, up 127.6% a year over 9 years.
Net income was $287M and the operating margin 37.1%, against -14466.5% in 2016.
The diluted share count rose 293% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Aurinia Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $173,000 | $418,000 | $463,000 | $318,000 | $50M | $46M | $134M | $176M | $235M | $283M |
| Cost of revenue | — | — | — | $0 | $0 | $1M | $6M | $14M | $28M | $33M |
| Gross profit | — | — | — | $318,000 | $50M | $45M | $128M | $161M | $207M | $250M |
| Research and development | $15M | $34M | $41M | $53M | $50M | $51M | $45M | $50M | $21M | $33M |
| Selling, general and admin | $7M | $12M | $14M | $22M | $97M | $174M | $196M | $195M | $172M | $102M |
| Operating income | -$25M | -$47M | -$55M | -$91M | -$104M | -$181M | -$111M | -$92M | -$5M | $105M |
| Interest expense | — | — | $0 | $39,000 | — | $0 | $0 | $3M | $5M | $4M |
| Pre-tax income | — | -$71M | -$53M | -$88M | -$103M | -$180M | -$106M | -$77M | $7M | $114M |
| Income tax | $0 | $0 | $73,000 | $144,000 | -$94,000 | $760,000 | $2M | $551,000 | $2M | -$173M |
| Net income | -$23M | -$71M | -$53M | -$88M | -$103M | -$181M | -$108M | -$78M | $6M | $287M |
| EPS (diluted) | — | — | -$0.63 | -$0.95 | -$0.87 | -$1.40 | -$0.76 | -$0.54 | $0.04 | $2.07 |
| Diluted shares | 35M | 77M | 85M | 93M | 118M | 129M | 142M | 143M | 146M | 139M |
| Gross margin | — | — | — | 100.0% | 100.0% | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% |
| Operating margin | -14466.5% | -11212.4% | -11930.9% | -28598.4% | -208.1% | -396.3% | -83.2% | -52.2% | -2.0% | 37.1% |
| Net margin | -13465.3% | -16935.9% | -11464.1% | -27794.0% | -204.9% | -396.8% | -80.7% | -44.5% | 2.4% | 101.5% |
Balance sheet
Fiscal years, from Aurinia Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $40M | $173M | $118M | $306M | $272M | $232M | $94M | $49M | $83M | $80M |
| Receivables | $86,000 | $109,000 | $217,000 | $368,000 | — | — | — | — | — | — |
| Inventory | — | — | — | $0 | $14M | $19M | $25M | $40M | $39M | $46M |
| Total current assets | $41M | $175M | $133M | $315M | $419M | $513M | $443M | $425M | $447M | $492M |
| Property, plant and equipment | $29,000 | $31,000 | $41,000 | $93,000 | $5M | $4M | $4M | $3M | $3M | $2M |
| Total assets | $57M | $190M | $146M | $324M | $464M | $543M | $471M | $548M | $551M | $752M |
| Total current liabilities | $8M | $8M | $7M | $11M | $32M | $41M | $46M | $77M | $98M | $94M |
| Total liabilities | $21M | $24M | $33M | $26M | $56M | $64M | $65M | $170M | $173M | $170M |
| Shareholders' equity | $36M | $166M | $136M | $299M | $408M | $479M | $405M | $378M | $377M | $581M |
| Net debt | -$40M | -$166M | -$118M | -$306M | -$272M | -$232M | -$94M | -$49M | -$83M | -$80M |
Cash flow
Fiscal years, from Aurinia Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19M | -$41M | -$52M | -$64M | -$70M | -$158M | -$80M | -$33M | $44M | $136M |
| Capital spending | $25,000 | $25,000 | $0 | $0 | $2M | $1M | $0 | $0 | — | — |
| Free cash flow | -$19M | -$41M | -$52M | -$64M | -$72M | -$159M | -$80M | -$33M | — | — |
| Stock-based compensation | $1M | $4M | $7M | $7M | $17M | $31M | $32M | $45M | $32M | $15M |
| Share buybacks (net) | — | — | — | — | — | — | $0 | $0 | -$40M | -$98M |
| Free cash flow margin | -10831.2% | -9855.0% | -11147.1% | -19995.3% | -142.7% | -348.4% | -59.3% | -19.1% | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AUPH.
Open AUPH in InvestinglyQuestions
What was Aurinia Pharmaceuticals's revenue in 2025?
$283M in fiscal 2025, from its 10-K filing.
From Aurinia Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.